Lantern Pharma Inc.
- LTRN
- NASDAQ
- Biotechnology
- AI-driven Drug Discovery
- Oncology Therapeutics
$0.64
Today −4.05%Quote Oct 19, 2026, 08:00 PM UTC
−58.63%over the last month
Max drawdown −58.6%From 1-month high −58.6%3 months −78.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Lantern Pharma
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
16
Market value
$8.2M
Quote Oct 19
Floor
$0.58
9.7% below price
Resistance
$0.71
11.4% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LTRNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free